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ETHICAL CONSEQUENCES OF FULL HUMAN 
GENOME TESTING 
Michael Lupton
 
A Genome is the entire set of hereditary instructions for building, 
running, maintaining an organism and passing on life to the next 
generation. A Genome is divided into chromosomes, the chromosomes 
contain genes and the genes are made of DNA. Genomes are found in cells; 
which are the microscopic structures that make up all organisms. With few 
exceptions, each of your body‟s trillions of cells contains a copy of your 
genome. The human genome may be commonplace but it is quite powerful, 
because the information in the genome affects every aspect of a person‟s 
behaviour and physiology. The refinement and perfection of the techniques 
involved has resulted in the reduction of the cost of sequencing to the 
current price of USD $1,000 and less. This means that the technology is 
now routinely available, and it is predicted that in another 5 years‟ time the 
tests will cost in the vicinity of USD $100, placing them on par with the 
current cost of an X-Ray or a biopsy, and truly within the ambit of an 
everyday diagnostic tool. The advantages of accurate diagnosis and 
treatment will be affected by a host of ethical problems. The most pertinent 
of these are: Incidental findings, confidentiality, responsibility. Incidental 
genetics findings are unexpected results which are unrelated to the reason 
for the test. However, if they unearth a gene variant that may cause a 
serious disease then nondisclosure is hard to justify. If a whole genome 
sequence reveals a number of clinically actionable variants should this 
information be passed on to third parties who might also be affected? 
Alternatively, what happens if the patient insists that the information be 
kept confidential? Whole genome sequencing will also impact on the 
concept of responsibility for health. Should such sequencing be used by 
prospective parents to determine the odds of them transmitting problematic 
gene variants to their children? If the parents are found to be at risk should 
they be allowed to resort to pre-implantation genetic diagnosis of their 
embryos in order to select only healthy embryos for implanting? These and 
other ethically relevant issues flowing from whole genome sequencing will 
be discussed in this paper. 
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INTRODUCTION 
As the price of whole genome sequencing continues to drop, the 
consequence thereof is that its use will become increasingly more prevalent 
by general practitioners. It is not far-fetched to assume that in ten years‟ 
time these tests will be as ubiquitous as the current blood tests in the 
practice of medicine.  
Part II of the article will examine the consequences of the continuing 
lowering of the costs of sequencing the whole genomes while Part III 
stressed the fact that the necessity for informed consent is undiminished. 
Part IV examines whether the genome can be the subject of ownership and 
thus whether it can be patented. Part V discusses the concept of patient 
autonomy and the professional judgment of doctors in the field of genomic 
medicine. Part VI stresses the vital importance the laws relating to privacy 
play in protecting a person‟s genetic information, while Part VII once again 
revisits the ethics applicable to incidental genetic findings arriving from 
sequencing the genome. Part VIII stresses the importance of sound genetic 
counselling for a patient whose genome has been sequenced. 
I. DEFINITION OF A GENOME 
A genome comprises the entire set of hereditary instructions required 
to build, run and maintain an organism, inclusive of passing on life to the 
next generation of that organism.1
 
                                                 
1 SARAH DE WEERDT, WHAT IS A GENOME? (Editor, Barbara J Culleton, 2003). 
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The genome of most living organisms is made of a chemical called 
DNA. The construction of the genome contains genes. The genes in them 
are packaged in chromosomes and they play a profound role
2
 in creating the 
specific characteristics of the said organism.
3
 In summary, the genome is 
divided into chromosomes, the chromosomes contain genes, and the genes 
are made of DNA. The locus of the genome is in the cells of the organism. 
These microscopic structures are the building blocks of all organisms. 
Although the genome is as commonplace as the trillions of cells in your 
body, which each contain a copy, it is a powerful force in your body. A 
genome contains information that affects every aspect of a person‟s 
physiology as well as its behaviour. Therefore every range and nuance of a 
person‟s life, such as thinking, talking, singing, sleeping or digesting food is 
influenced by that person‟s genome.4 
A study of the human genome will reveal insights into why some 
people die of heart disease while others die of cancer, why some people are 
confident and extroverted in a crowd while others are shy and retiring. Each 
human being contains a slightly different version of the human genome, but 
all human genomes are similar enough that we can learn about the human 
genome in general by studying the genomes of a few individual people.
5
 
II. THE STUDY OF THE HUMAN GENOME 
Until very recently genetic testing was limited to sequencing single 
genes. Whole genome sequencing (hereinafter WGS) is also known as full 
genome sequencing, complete genome sequencing or entire genome 
sequencing. It involves a laboratory process that determines the complete 
DNA sequence of an organism‟s genome in a single process. This process 
entails sequencing all of an organism‟s chromosomal DNA as well as the 
DNA contained in the mitochondria.
6
 WGS enables scientists to identify 
variants in an individual‟s genome that may contribute to ill-health.7  
A. Sequencing Versus Analysis 
Full human genome sequencing (WGS) of an individual‟s DNA will 
                                                 
2 Ibid. 
3 Ibid. 
4 Ibid. 
5 Ibid. 
6 A. Coombs, The Sequencing Shakeup, 26 NATURAL BIOTECHNOLOGY 1109—1112 (2008). 
7 Carwyn Hooper, The Genome Revolution Is Coming and with Some “Big Dilemmas”, THE 
CONVERSATION (22 June 2015). 
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provide raw data on all six billion nucleotides in an individual‟s DNA.8 
Once WGS has been completed the information is provided, then it is 
available for analysis by experts. This analysis will in turn reveal all the 
disease-related genetic variants in that genome. The analysis will facilitate a 
prediction of what diseases a person may be afflicted with in the future. This 
will allow his physicians to take steps to minimize the impact of that disease 
or to avoid it altogether through the implementation of personalised 
preventative medicine.
9
 Jay Flatley, the CEO of Ilumina, has predicted that a 
WGS for every newborn will be technically feasible and affordable by 
2020.
10 
This potential use of genomic sequencing would be controversial as 
it contradicts established ethical norms for the use of genetic tests. These 
tests are not normally used to conduct predictive testing on asymptomatic 
minors. Established ethics dictates that the tests are to be used to identify 
genetic markers associated with disease. It thus appears that in order to 
accommodate WGS the medical profession will have to change its 
traditional norms.
11
 
B. Sequencing Techniques and Cost Reduction 
The perfection of high throughput sequencing techniques by 2001 
enabled the entire human genome to be sequenced in 10 months at a cost of 
5 US cents per base pair. Ongoing improvements in efficiency have meant 
that the goal now is to reduce the price to below 1 US cent per base pair by 
2020.12
 
This goal is likely to be achieved by developing cheaper and quicker 
ways of preparing DNA for reading by automatic sequencers resulting in 
fewer passes and assembly issues. Reading techniques will also become 
cheaper and quicker as a result of a US patent granted on an invention which 
places DNA on a chip. The chip then passes through on optical detector that 
records the DNA in much the same way as an optical sensor in a DVD 
player does. According to its inventors this device has the potential to 
decipher an entire genome in the 30 minutes and it takes DNA to replicate 
                                                 
8 SB Ng et al., Exome Sequencing Identifies the Cause of a Mendelian Disorder, 42(1) NATURE 
GENETICS 30—35(2010). 
9 L. L. McCabe & E. R. McCabe, Postgenomicmedicine Presymptomatic Testing for Prediction and 
Prevention, 28 CLINICAL PERINATAL 425—434 (2001). 
10 Mark Henderson, Genetic Mapping of Babies by 2019 Will Transform Preventative Medicine, 
LONDON TIMES. Online www.timesonline.co.uk /tol/news/uk/science/article 5689052. 
11 P. Barry et al., Genetic Testing in Asymptomatic Minors. Background Considerations, 17 
EUROPEAN JOURNAL OF HUMAN GENETICS 711 (2009). 
12 T. A. Robertson, The $1000 Genome: Ethical and Legal Issues in Whole Genome Sequencing of 
Individuals, 3(3) AMERICAN JOURNAL OF BIOETHICS 35—42 (2003).  
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itself.13
 
C. Use of Genetic Analysis as a Predictor of Future Diseases 
In the early years of the 21st Century the health industry harboured 
high expectations that the cures for a raft of as then untreatable diseases 
would be delivered by the fruits of the Human Genome Project and that 
cures were just around the corner. This excitement and expectation was 
driven by the fact that our understanding of the clinical relevance of genetic 
variants was improving rapidly and that the USD $1,000 genome sequence 
had arrived. We should however retain our rational perspective and not 
surrender to, nor be blinded by all the hype surrounding genomics.14
 
Scientists require an ongoing flow of money to continue their research. 
They have seduced the media with wildly extravagant representations of 
their progress in the field of WGS and the politicians who supply the 
research dollar have deemed it expedient to jump on the science bandwagon 
and provide the pump priming dollars that keep the caravan rolling 
forward.15 
Let us place genome research into context. In 2007, ten years after the 
full yeast genome of 6,000 genes had been sequenced 1,000 of those genes 
had not yet been characterised. As far as humans are concerned the situation 
is even grimmer, currently the bulk of our biological knowledge (perhaps as 
high as 99.9%) is linked to less than 1% of the human genome.
16
 
It is estimated that roughly 10,000 to 15,000 human genes require 
functional characterization to get a sound understanding of what the gene 
protein is all about and to close gaps at the level of molecular, cellular or 
phenotypic function. 
17 
The records show that at current rates of analysis about 100 genes are 
characterised per year. Why is it so difficult to discover the function of a 
gene? 
First, no molecular function has emerged out of large—scale studies. 
This is because the specific biological effects of the genes‟ functions are 
individual affairs which require creative, gene specific tailored approaches, 
                                                 
13 Op. Cit., at 36. 
14 E. S. Lander et al., Initial Sequencing and Analysis of the Human Genome, 409 NATURE 860 (2001). 
15 F. Eisenhaber, A Decade after the Firstfull Human Genome Sequencing, When Will We Understand 
Our Own Genome, 10(5) JOURNAL OF BIOINFORMATICS & COMPUTATIONAL BIOLOGY (2012). 
16 L. Pena-Castillo & T. R. Hughes, Why There Are Still Over 1,000 Uncharacterised Yeast Genes? 
176 (7) GENETICS 7—14 (2007). 
17 E. Birney et al., Identification and Analysis of Functional Elements in 1% of the Human Genome by 
the ENCODE Pilot Project, 447 NATURE 799—816 (2007). 
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that resist generalised handling. All of these points to the fact that 
researchers have a long way to go before the large scale personalised 
medical dream is delivered.
18 
III. INFORMED CONSENT 
A. Informational Content 
A doctor must obtain informed consent from a patient before he can 
remove DNA from his body. The informed consent requirement in turn 
protects the patient‟s right to decide whether in fact he wishes to provide the 
doctors with a sample of his tissue. The patient may thus reserve for himself 
the right not to provide the tissue if the intention is to subject the tissue to 
tests or for it to be sequenced for purposes unacceptable to the patient.
19
 
Consent to removal of tissue per se does not extend to consent or the 
creation of rights to develop genomic information from that DNA. This 
denial also extends to the use of DNA retrieved from objects a person has 
touched or discarded.
20
 The arrival of the $1,000 dollars genome (and 
cheaper) will result in vastly more genetic information being gathered from 
individuals. It should also serve as a warning to patients to ensure that they 
obtain legal control over their DNA samples and also over the information 
they contain.
21
 
Informed consent serves as the corner stone of ethical research conduct 
and aims to protect research subjects against coercion, deception and 
abuse.22  Public policy and ethical guidelines stipulate that the following 
requirements regarding genetic testing should be met: 
 No physician, laboratory or other entity may sequence, store or test 
identifiable DNA unless the person tested has given written, informed 
consent. 
 Researchers should inform an individual of the relevant risks and 
benefits of the proposed sequencing and testing prior to taking samples from 
him. 
 The consent must be both free and informed. 
                                                 
18 Ibid. 
19 Welcome Trust Sharing Data from Large-Scale Biological Research Targets. A System of 
Tripartite Responsibility (2003). 
20 D. M. Wendler et al., Does the Current Consent Process Minimize the Risks of Genetic Research?, 
113 AMERICAN JOURNAL OF MEDICAL GENETICS 258 (2002). 
21 Ibid. 
22 W. Pinxter et al., Ethical Issues Raised by Whole Genome Sequencing, 28(2) BEST PRACTICE & 
RESEARCH CLINICAL GASTROENTEROLOGY 269 (2014). 
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 The signed consent document also serves the purpose of enabling 
researchers to defend themselves against accusations of unethical research 
conduct. 
23
 
Researchers face the following challenges in obtaining an informed 
consent: 
 The potential for information overload. 
 The complexity of the information. 
 The limited ability of individuals to sufficiently understand or 
remember the information given. 
 Biased understanding and false hopes. 
 A vast volume of complex genetic information. 
 The possibility of generating information about the future health 
status or health risks posed to relatives. 
 It would also be ethically correct for researchers to be vigilant in not 
overselling the benefits of WGS in clinical applications.
24
 
IV. ETHICAL CONCERNS 
There is little doubt that a person owns and controls access to his DNA, 
while the DNA is contained in his body. 
Once DNA is removed from a person‟s body there are immediate legal, 
social and ethical issues which arise in relation to the control, acquisition 
and use of that DNA and the information it contains.
25
 
The ethical and legal challenges that apply to excised DNA is how to 
fairly resolve the ownership, consent, privacy, and use of the information 
revealed by tests on the DNA. A fair resolution of these issues is vital to 
ensure that consumers and the public will have confidence that whole 
genome sequencing will benefit rather than harm them.
26 
A. Can the Genome Be the Subject of Ownership  
In order to determine who has ownership (or dispositional control)     
of an individual‟s genome it is necessary to distinguish the following   
issues: 
 
                                                 
23 Robertson, Op. Cit., at 38. 
24 Pinxter, Op. Cit., at 271—272. 
25 H. Varmus, Getting Ready for Gene-Based Medicine, 347 NEW ENGLAND JOURNAL OF MEDICINE 
1526 (2002). 
26 Robertson, Op. Cit., at 37. 
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1. Physical Embodiment 
By physical embodiment we mean a tissue sample that contains the 
DNA or DNA molecules which have been separated from it. In this instance 
it is necessary to decide whether to apply a property rule or a liability rule.27 
If a property rule is chosen a person would have dispositive ownership over 
the DNA in his body and continue to do so unless or until they abandon 
their DNA or cede rights in it to third parties.28 
If a liability rule is used then it would mean that a third party would be 
required to pay the owner damages for intruding on their body to obtain 
their DNA and then using it without their consent. The application of this 
rule would mean that it would not give any rights to third parties in DNA 
that was taken from the owners‟ body without informed consent. It would 
further not create any rights in DNA found on postage stamps, envelopes or 
cigarette butts.29 The leading case of Moore v. Regents of the University of 
California30 adopted a liability, rather than a property approach, to resolve a 
dispute about the commercial exploitation of a patient‟s spleen cells. The 
patient‟s spleen was removed and his cells used to develop a patented cell-
line without obtaining the patient‟s consent to do so.31 
The court held that Moore (the patient) had a right to informed consent 
in relation to the removal and use of his cells. The court however rejected 
his claim that he retained a property right in the tissue after it had been 
removed from his body.32
 
B. Patenting the Human Genome 
There is great medical importance that attaches to the sequencing of the 
human genome. The science and testing involved in the process of 
determining the function of human genes will have consequences regarding 
the amount of venture capital invested in genetic research and also in 
turning the results of this research into economic outcomes. In order to 
achieve these results the law of intellectual property will play a significant 
role. Without the protection patents offer venture capital investment the 
                                                 
27 B. M. Knoppers et al., The Emergence of an Ethical Duty to Disclose Genetic Research Results: 
International Perspectives, 14(11) EUROPEAN JOURNAL OF HUMAN GENETICS 1170 (2006). 
28 Robertson, Op. Cit., at 37. 
29 Ibid. 
30 793 P (2d) 479 (1990). 
31 Ibid. 
32 Ibid. 
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genomic revolution will dry up.
33
 The other issue in the field of patents is 
that scientists have for many years collected samples from the populations 
in developing countries whose inhabitants have a rich diversity of genetic 
materials. This material was used to develop therapies which would in turn 
only be available to the countries of origin under costly licensing 
agreements. The participating countries are now insisting on a “genomic 
dividend” for their countries out of the profits derived from their DNA 
source material.
34
 
1. Patenting the Breast Cancer Gene  
On the 7th October 2015, all seven judges of the High Court of 
Australia, in the case of D‟Arcy v. Myriad Genetics Inc.35 overturned the 
earlier unanimous decision of a five judge bench of the Full Federal Court 
when they held that an isolated nucleic acid, coding for a mutant BRCA1 
protein, was not a “patentable invention” under the Australian Patents Act. 
The decision related to Australian Patent no. 686004 which was filed in 
August 1995 and which had recently expired. The High Court‟s decision has 
now closely aligned Australia‟s position to that of the US Supreme Court in 
its decision on Myriad Genetics claim for a patent in the USA.
36 
In its decision in Myriad the Full Federal Court had characterised the 
claimed isolated nucleic acid as a compound rather than information.
37 
In its 
judgement the High Court differed and held that, to say that the claims 
relate to a class of chemical compound elevates “form over substance”. In 
the High Court‟s judgment they held that a sequence of nucleotides, whether 
genomic DNA or cDNA, should properly be described as “information”: 
“… the information stored in the sequence of nucleotides coding for 
the mutated or polymorphic BRCA 1 polypeptide is the same information as 
that contained in the DNA of the person from which the nucleic acid was 
isolated. It is the existence of that information which is an essential element 
of the invention as claimed. The product is the medium in which that 
information resides.”38  Myriad did not create this information it already 
existed in the individual, Myriad merely isolated and extracted the Nucleic 
                                                 
33 Ibid. 
34 Eisenhaber, Op. Cit., at 6. 
35 [2015] HCA 35. 
36 Association for Molecular Pathology v. Myriad Genetics Inc. 186 L Ed 2d 124 (2013); See also in 
the U.K. Human Genome Sciences Inc. v. Eli Lilly v. UKSC 51 60 [2011]. 
37 D‟Arcy v. Myriad Genetics Inc. [2014] 313 ALR627. See also, B. Sherman D‟Arcy v. Myriad 
Genetics Inc., Patenting Genes in  Australia, 37 (1) SYDNEY LAW REVIEW (2015). 
38 D‟Arcy v. Myriad Genetics Inc., Op. Cit., paras. 54—61. 
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acid. The information itself could therefore not be considered a new manner 
of manufacture.
39
 
In this decision the High Court judges in large part have reinvented the 
test for patentable subject matter formulated in the decision in National 
Research Development Corporation v. Commissioner of Patents40 (NRDC) 
which was decided in 1959 and which was upheld as recently as 2013 by the 
High Court in Apotex v. Sanofi Aventis.41
 
The High Court also acknowledged the fact that where a new class of 
claims such as those in dispute in Myriad arose and which involved negative 
policy implications which could have the effect of stifling innovation that it 
was not the role of the Courts but rather that of Parliament to spell out in 
legislation whether such claims should be patentable.42 
2. Effect of the Decision on Gene Patents 
Technological advancements are endemic in the biotechnology 
industry. In this regard Myriad provides some reprieve to patentees because 
the High Court (unlike the US Supreme court) has not made prospective 
statements about gene patents in its judgment. It limited its decision to the 
specific claims made by the appellant. The High Court also stressed that the 
decision did not extend to any of the other claims listed in Myriad‟s Patent 
on BRCA 1.43 
Despite the narrow focus of the High Court‟s decision existing patents 
based on genetic sequences may now be vulnerable to challenges. IP 
Australia has also issued a statement that it has suspended the examination 
of patent applications claiming nucleic acid sequences until it has fully 
studied the implications of the High Court decision.44 
In the light of the applicant‟s victory, it will be interesting to see 
whether it translates into a reduction of the alleged high cost of breast 
cancer screening. 
V. DOCTRINE OF PATIENT AUTONOMY VERSUS PROFESSIONAL JUDGMENT IN 
GENOMIC MEDICINE 
The evolution away from medical paternalism to patient autonomy is 
                                                 
39 Ibid, at paras. 86—90, 110—113. 
40 [1959] HCA 67. 
41 [2013] HCA 50. 
42 D‟Arcy v. Myriad Genetics Inc., Op. Cit., paras. 25—28, 135—137. 
43 Ibid, at para. 191. 
44 Ibid. 
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now firmly entrenched in the ethics of medical practice. Medical 
practitioners are now trained to respect the individual autonomy of their 
patients and the fact that a patient has a right to be wrong. However, the 
dangers of unfettered autonomy are perhaps nowhere greater than in the 
field of genomic medicine where it could lead to direct genetic testing which 
in turn could lead to clinically unwise health related decision making.
45
 
Professional judgment is more vital than ever given the fact that a 
patient is able to approach companies that provide WGS on a direct to 
patient basis.  
In most clinical situations the illness being tested for in individuals 
involves only a selected set of genes that need to be analysed. The analysis 
of only a selected group of genes will minimise confusion and also reduce 
the risk of false positive results.
46
 
The above situation can be illustrated with the following example. A 
physician is seeking to establish why a particular patient has a 
predisposition to cancer. The option of the USD $1,000 WGS makes it 
economically feasible to opt for WGS in this diagnostic setting, but it is not 
professionally responsible to analyse a mass of genes which probably have 
no bearing on the condition for which the test was ordered. For example, 
what possible relevance can querying the status of the patients‟ PSEN1 have 
(which, when mutated, strongly predisposes a patient to early onset 
Alzheimer disease) when the required diagnosis is directed at cancer causing 
mutations.
47 
On the other hand if the object has a research focus, one aimed at gene 
discovery, then there are clear benefits to be gained from sequencing the 
entire genome. It is thus clear that professional judgment in the field of 
genomics is essential for responsibly determining the optimal approach. 
48
 
The interpretation of WGS results also requires professional 
knowledge and careful expert planning. Once the results are available a 
doctor must be able to interpret the results so as to determine what level of 
evidence is required before assigning pathogenicity to a particular variant of 
which there will be many.
49 
                                                 
45 B. M. Knoppers et al., The Emergence of an Ethical Duty to Disclose Genetic Research Results: 
International Perspectives, 14 EUROPEAN JOURNAL OF HUMAN GENETICS 1170 (2006). 
46 K. L. Brierlyet al., Adverse Events in Cancer Genetic Testing: Medical, Ethical, Legal and 
Financial Implications, 18 CANCER JOURNAL 303 (2012). 
47 Ibid, at 304. 
48 E. W. Clayton, Ethical, Legal and Social Implications of Genomic Medicine, 349 NEW ENGLAND 
JOURNAL OF MEDICINE 562 (2003). 
49 R. Langreth, Fumbled DNA Tests Mean Peril for Breast Cancer Patients, BLOOMBERG NEWS (10 
September, 2012). 
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It is important for individuals who undergo a genetic sequencing, to 
have confidence in the recommendations made to them and in the doctors 
making those recommendations. When such recommendations have clinical 
implications and are made on the basis of genomic information, then the 
individual becomes a patient and this interaction becomes part of medical 
practice which in turn requires the involvement of a licenced health care 
provider.
50
 
The above examples clearly illustrate the fact that clinical judgment is 
essential in the practice of medicine. As the practice of WGS becomes more 
common an ever increasing number of high stakes decisions will be made 
on the basis of complex genomic information. At the current fairly low 
levels of usage of genomic analysis, misinterpretation of genomic data by 
medical professionals without adequate genetic knowledge has resulted in a 
wide range of harm to patients. The consequences have varied from failure 
to recommend necessary risk-reducing measures for at risk individuals to 
unnecessary surgery for those actually at normal risk.
51 
It is thus abundantly clear that the aggressive marketing of direct-to 
consumer genomics, in the absence of expert professional judgment, poses 
special challenges and should only be sanctioned under regulated 
circumstances.52
 
VI. DATA DISCLOSURE, PRIVACY AND DISCRIMINATION 
Most ethicists agree that the privacy of individuals undergoing WGS, 
or more limited genetic sequencing, must be protected at all costs. The 
reason for this is that the information revealed from such sequencing will 
not only disclose a great deal of sensitive information about the individual‟s 
DNA, his present and future health risks, but it can also reveal information 
about the DNA sequences of close relatives.
53
 
Examples include demographic information, clinical information (or 
portions of an individual‟s medical records), exposure of employment 
histories and family pedigrees amongst other linked data. Such information 
may be sought by a variety of third parties, including employers, insurers, 
                                                 
50 S. E. Plon et al., IRRC Unclassified Genetic Variants Working Group. Sequences Variant 
Classifications and Reporting Recommendations for Improving the Interpretation of Cancer 
Susceptibility Genetic Test Results, 29(11) HUMAN MUTATIONS 1282 (2008). 
51 K. L. Brierley, Op. Cit., at 303. 
52 Ibid. 
53 B. A. Malin, How (Not) to Protect Genomic Data Privacy in a Distributed Network: Using Trail 
Re-identification to Evaluate and Design Anonymity Protection Systems, 37 JOURNAL OF BIOMEDICAL 
INFORMATION 179 (2004). 
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courts of law and family members. The latter parties could all use this 
information to the detriment of the individual. It is imperative that there are 
appropriate legal safeguards against such unintended usage.
54 
At the most basic level of protection the person whose DNA is 
sequenced should have the right to decide whether, and how, identifiable 
medical information about him is obtained, used, or disclosed to others. 
The common law principles of tax and property law will provide some 
protection, but in Australia, the Privacy Act is likely to provide more 
substantial protection, especially via Privacy Principle two and three which 
deal with Anonymity and Pseudonymity, and the collection of solicited 
personal information.
55 
The Privacy Act makes provision for an individual to pursue both 
civil
56
 and criminal proceedings
57
 against a third party who sequences, uses 
or transfers identifiable DNA of another person without that person‟s 
permission. 
In addition to the above legislation the privacy of genetic information 
can also be protected via contract. Thus if individuals have dispositional 
rights over their DNA plus the information originating from that source, 
then they can refuse to provide DNA for sequencing or testing unless the 
privacy of the results is protected in terms of the owner‟s express consent 
set out in the contractual conditions agreed to when the owner undertook to 
provide DNA for genotype testing.
58
 
Without strong safeguards to ensure privacy, the risk that contributed 
DNA could be used in unauthorised ways may discourage patients from 
utilising this ultimate diagnostic tool.
59 
A. Obligations to Share Information with Family Members 
A major risk of sequencing an individual‟s whole genome is that much 
more medical information will be known about him and his family than he 
might find acceptable. Nor would he want others to know about late onset 
diseases or about behavioural tendencies which he/she could do little to 
prevent, especially if that information could lead to stigmatization or 
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discrimination.60
 
The generation of WGS data significantly increases the ability to match 
the DNA of close relatives, and to reveal predictive information about 
relatives‟ present and future health risks. This also raises important 
questions about what obligations, if any, a patient who has submitted to 
WGS owes to family members. The probability of, and risks associated with 
identification, must be balanced against the scientific and clinical usefulness 
of the data and the rights and autonomy of individuals to participate in 
genetic research without interference from more risk-averse family 
members.61 
The ethical obligations towards relatives increase as the risk to them 
intensifies. However, in the light of autonomy-based consent principles it 
seems inappropriate to suggest that participants have a right to deny use of 
the information.62
 
It is therefore submitted that researchers conducting WGS should, as a 
matter of course discuss with participants the implications for family 
members, and they should include close genetic relatives in the decisions 
about research participation prior to it occurring. The obligation to include 
at risk relatives in the decision making process increases as the degree of 
consanguinity with the research participant becomes closer.63
 
If family members raise objections should they be investigated by a 
relevant research ethics review board? An extensive literature exists on the 
obligation to warn at risk family members of genetic risks which can be 
exposed by WGS.64
 
The unauthorised disclosure of genetic risks is only permitted in the 
most extreme circumstances, and only after attempts to encourage voluntary 
disclosure on the part of the patient has failed. Furthermore the harm must 
be highly likely to occur, or be seriously imminent and foreseeable. The at 
risk relative must be identifiable, the disease preventable, treatable or it 
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must be clear that early monitoring will reduce the genetic risk.65
 
B. Protecting against „Unfair‟ Genetic Discrimination 
Public opinion is strongly opposed to “genetic discrimination” in the 
fields of health insurance and employment. This opposition is based on the 
fear that a person‟s access to health care and jobs will be impaired by 
involuntary disclosure.66
 
It is however, accepted that certain existing genetic conditions might 
predispose some persons to injury in certain industries like beryllium 
mining. Therefore testing to eliminate such persons from exposure to fatal 
risks is justifiable.67 
Access to a person‟s whole genotype could also result in refusal by 
insurance companies to sell life and health insurance to an applicant on the 
basis that it would be to the detriment of other policy holders. Such a refusal 
would be motivated as protecting existing policy holders against higher 
premiums by not admitting persons with a much higher genetic risk of 
illness. The passing of the Genetic Information Non-discrimination Act in 
the United States will, however, ensure that participants undergoing WGS 
will not be adversely affected in their access to jobs or health insurance.68 
The prevalence of identity theft is a growing problem which might 
discourage many from reducing their “genetic identity” to a computer file 
which could be stolen and misused. For example, such theft could result in 
unauthorised testing or disclosures that may lead to stigma and 
discrimination. The information on the file could also be used to determine 
identity or kinship relationships that the owner would prefer not to reveal in 
order to avoid personal embarrassment or legal actions.69 
VII. THE ETHICS RELATED TO INCIDENTAL GENETIC FINDING (IFS) 
Incidental findings are the subject of intense ethical debate in medical 
genomic research. We also need to determine whether this debate is 
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focussed on the right issues.70 
IF‟s usually occur when a patient submits to WGS in order to 
investigate a specific condition. Such widespread testing will, in its very 
nature, reveal other conditions as well that are unrelated to the reason for the 
test but which may be clinically relevant.71 
The ethical issues that arise from such information have implications 
for patients, researchers and physicians. These implications relate mainly to 
decisions on how best to prepare patients for the potential discovery of IF‟s 
during the informed consent process. The following issues are also relevant: 
 Are researchers obliged to report IF‟s to physicians. 
 Do research participants have the right to be informed or not to be 
informed about IF‟s.72 
The answer to these questions depends in part on whether the 
incidental finding occurs during the course of research or whether it occurs 
in the context of clinical practice. If the gene variant detected is likely to 
cause a serious disease and if an early diagnosis will retard the development 
(or reduce the severity) of the disease, then it is hard to justify nondisclosure. 
On the other hand, if the clinical relevance of a gene variant is unclear and if 
there is limited evidence about the predictive variant it is less clear whether 
such information should be given to the patient.73 
Withholding health data is reminiscent of medical paternalism which is 
in stark contrast to the rights of access to health records which 21st Century 
patients demand, and this includes the results of any test performed on them. 
However, withholding certain parts of test results may be construed as a 
breach of patient autonomy in situations where there is genuine uncertainty 
about the risks posed by IF‟s. In such situations a small dose of paternalism 
may be judicious.
74 
VIII. GENETIC COUNSELLING AND WHOLE GENOME SEQUENCING 
The magnitude and complexity of the information generated by WGS 
is such that without both pre- and post-test genetic counselling by qualified 
professionals the test results are of little value to the patient or could 
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actually be dangerous if incorrectly interpreted by a genetic practitioner with 
only limited training.
75
 
The value of competent genetic counselling cannot be overestimated. 
This fact is illustrated when tests are done for genes which predispose to 
multifactorial disorders but which convert into only a small risk of disease 
or for which the precise risk of disease may not even be clearly known.
76
 
The above scenario is becoming increasingly more common as genetic 
tests are being prescribed more often by primary care givers for their 
patients. In order to avoid problems that can arise for a patient from lack of 
understanding, the European Commission has endorsed non-directive (non-
coercive) genetic counselling as the gold standard. The Commission also 
recommended that no patient should be permitted to embark on genetic 
testing without prior counselling.
77
 
The availability of direct to consumer genetic testing is indicative of 
the potential danger lurking in the disconnect between the supply of genetic 
services on a random basis unaccompanied by any counselling by 
professionals. For example commercial genetic testing laboratories are now 
marketing genetic tests for breast cancer (BRCA1 and BRCA2) cystic 
fibrosis, as well as non-clinical tests for nutrition, directly to consumers.
78
 
This strand of direct to consumer marketing has been shown to lead to 
inappropriate utilization of test results, misinterpretation of results and lack 
of necessary follow up. The problem is being compounded by internet 
marketing to consumers plus a variety of „home testing‟ kits which are now 
available.
79 
Unlike the USA, Australia has not yet legislated to control genetic 
testing or to make counselling mandatory. It has instead relied on the 
guidelines issued by the Australian Government via the National Health and 
Medical Research Council.
80
 
This document is also reinforced by the guidelines on genetic testing 
issued by the Australian Medical Association in 2012 entitled “Genetic 
Testing 2012”. Australia and New Zealand have also created guidelines to 
ensure the quality control of genetic testing done in many laboratories in 
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their countries.
81
 
For Laboratories to attract a government subsidy for the genetic tests 
they perform, they must make an application to the Medical Services 
Advisory Committee which advises the Federal Government on new 
medical technologies and procedures.
82 
CONCLUSION 
Genetic knowledge can be perceived either as a means to enhance 
control of person‟s lives or as a sign of predestination written in a 
mysterious “future diary” because the full DNA sequence of the human 
genome now gives us an unprecedented opportunity to observe and 
understand the Book of Life.
83 
As Genome technology moves from the laboratory to the health care 
setting the WGS technology will enable geneticists to foretell future disease 
and alert patients and their health care providers to embark on better 
preventative strategies. If an individual‟s WGS analysis falls into the wrong 
hands it could be used to stigmatise a person or to discriminate against that 
person. Therefore data control measures and Privacy Laws need to be 
strengthened to guard against such eventualities.
84
 
It is also important to retain a sense of balance in regard to the potential 
of the Human Genome because of the great expectations that the HGP 
would lead to massive commercial and medical applications has to date 
turned out to be over-optimistic and highly inflated. In the words of Francis 
Collins, “… it is fair to say that the HGP has not as yet directly affected the 
health care administered to most individuals”.85 While Craig Venter, the 
other giant in the field of the HGP, is on record as saying that “… there is 
still some way to go before this capability can have a significant effect on 
medicine and health”.86 
The main fruits of the HGP have been accruing to the research 
community, and almost nothing as yet to medicine and the general public.
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When the benefits do start flowing to the field of medical practice it will 
create a serious demand for medical geneticists and genetic counsellors 
because inevitably our concept of disease will become increasingly 
“geneticised”.88 
The new era of personalised medicine based on genomic profiles will 
demand higher levels of safety, reliability and clinical value for all genetic 
tests on offer. Patients, their families, and the public must be protected 
against any untoward social, ethical and legal consequences of genetic 
testing. Serious consideration should be given to immediately embarking on 
drafting a Genetic Bill of Rights which will have provisions to regulate and 
protect all communities for the advent of the genomic age.
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